Dashboard
Manage Tickers

BEAMBeam Therapeutics Inc.

Nasdaq beamtx.com


$ 22.47 $ 0.31 (1.4 %)    

Thursday, 09-May-2024 15:01:03 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.22 $ 0.76 (0.17 %)
DIA $ 393.77 $ 3.66 (0.94 %)
SPY $ 519.77 $ 2.33 (0.45 %)
TLT $ 90.74 $ 0.70 (0.78 %)
GLD $ 216.34 $ 1.64 (0.76 %)
$ 22.24
$ 22.16
$ 21.99 x 100
$ 22.50 x 100
$ 22.08 - $ 22.77
$ 16.95 - $ 49.50
1,020,211
na
1.82B
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

barclays-maintains-equal-weight-on-beam-therapeutics-lowers-price-target-to-33
Barclays Maintains Equal-Weight on Beam Th...
05/08/2024 18:03:40

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $4...

beam-therapeutics-ended-q1-2024-with-11b-in-cash-cash-equivalents-and-marketable-securities-cash-runway-expected-to-support-operating-plans-into-2027
Beam Therapeutics Ended Q1 2024 With $1.1B...
05/07/2024 10:39:46

beam-therapeutics-q1-2024-gaap-eps-121-beats-144-estimate-sales-7410m-miss-16967m-estimate
Beam Therapeutics Q1 2024 GAAP EPS $(1.21)...
05/07/2024 10:38:59

expert-ratings-for-beam-therapeutics
Expert Ratings For Beam Therapeutics
04/23/2024 18:00:16

wedbush-reiterates-outperform-on-beam-therapeutics-maintains-57-price-target
Wedbush Reiterates Outperform on Beam Ther...
04/23/2024 16:32:11

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $57 price target.

popular-crypto-trader-shares-2024-predictions-for-these-three-altcoins
Popular Crypto Trader Shares 2024 Predicti...
04/12/2024 17:55:11

Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitr...

gene-therapy-side-effects-verve-therapeutics-halts-enrollment-of-lead-gene-therapy-trial-in-patients-with-bad-cholesterol
Gene Therapy Side Effects: Verve Therapeut...
04/02/2024 16:19:14

Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regul...

expert-outlook-beam-therapeutics-through-the-eyes-of-4-analysts
Expert Outlook: Beam Therapeutics Through ...
03/27/2024 15:01:00

bmo-capital-maintains-outperform-on-beam-therapeutics-maintains-57-price-target
BMO Capital Maintains Outperform on Beam T...
03/27/2024 14:12:12

BMO Capital analyst Kostas Biliouris maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $57 price tar...

beam-therapeutics-announces-clearance-of-clinical-trial-authorisation-application-for-beam-302-for-the-treatment-of-alpha-1-antitrypsin-deficiency-aatd
Beam Therapeutics Announces Clearance of C...
03/26/2024 10:31:25

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

navigating-4-analyst-ratings-for-beam-therapeutics
Navigating 4 Analyst Ratings For Beam Ther...
02/28/2024 15:00:23

rbc-capital-maintains-sector-perform-on-beam-therapeutics-raises-price-target-to-35
RBC Capital Maintains Sector Perform on Be...
02/28/2024 14:58:57

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and raises the price target fr...

why-helix-energy-solutions-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Helix Energy Solutions Shares Are Trad...
02/27/2024 18:18:56

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

norwegian-cruise-line-posts-strong-sales-joins-hims--hers-health-sterling-infrastructure-and-other-big-stocks-moving-higher-on-tuesday
Norwegian Cruise Line Posts Strong Sales, ...
02/27/2024 15:27:54

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

recap-beam-therapeutics-q4-earnings
Recap: Beam Therapeutics Q4 Earnings
02/27/2024 13:25:11

beam-therapeutics-q4-eps-173-vs-054-yoy-sales-31619m-beat-1867m-estimate-cash-runway-of-12b-expected-to-support-operating-plans-into-2027
Beam Therapeutics Q4 EPS $1.73 Vs $(0.54) ...
02/27/2024 11:34:24

cathie-wood-trims-nvidia-shopify-stakes-to-pump-whopping-40m-into-pinterest-despite-q4-revenue-miss
Cathie Wood Trims Nvidia, Shopify Stakes T...
02/09/2024 04:49:48

jp-morgan-upgrades-beam-therapeutics-to-overweight-raises-price-target-to-40
JP Morgan Upgrades Beam Therapeutics to Ov...
01/29/2024 10:43:38

JP Morgan analyst Eric Joseph upgrades Beam Therapeutics (NASDAQ:BEAM) from Neutral to Overweight and raises the price targe...

bitcoin-ethereum-dogecoin-rise-as-investors-weigh-spot-etf-impact-analyst-says-scenario-for-king-crypto-is-rejection-at-46k-and-then-correction-to-below-40k
Bitcoin, Ethereum, Dogecoin Rise As Invest...
01/17/2024 02:50:25

Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by

beam-therapeutics-reports-progress-across-hematology-and-genetic-disease-portfolios-cash-runway-expected-to-support-operating-plans-into-2027
Beam Therapeutics Reports Progress Across ...
01/08/2024 11:39:52

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION